Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    celecor
Previous Study | Return to List | Next Study

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI (CELEBRATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04825743
Recruitment Status : Recruiting
First Posted : April 1, 2021
Last Update Posted : May 18, 2022
Sponsor:
Information provided by (Responsible Party):
CeleCor Therapeutics

Brief Summary:
This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospitals in Europe and North America. Hospitals and ambulance services with experience in ambulance studies will be selected. Each subject will receive a single subcutaneous injection containing either zalunfiban Dose 1 (0.110 mg/kg) or zalunfiban Dose 2 (0.130 mg/kg) or placebo

Condition or disease Intervention/treatment Phase
ST-elevation Myocardial Infarction (STEMI) Drug: zalunfiban Drug: Placebo Phase 3

Detailed Description:

Subjects will be screened in the ambulance based on the information available; those fulfilling the eligibility criteria who have provided verbal witnessed/short written/Exception from Informed Consent Requirements (EFIC) process informed consent will be randomized and enrolled in the study. Following a single weight-based dose of subcutaneous study drug administered by the ambulance staff, the patient will be transferred to the clinical site PCI center for angiography and intervention.

Regular standard of care is performed from the provision of informed consent through the last study mandated subject visit. Concomitant medications will be recorded. Treatment with IV P2Y12 antagonists or other αIIbβ3 receptor before PCI/angiography is prohibited. Demographics, concomitant medications, vital signs, and medical history will be collected in the CRF. Adverse events, bleeding events and injection site reactions will be collected. Angiography and PCI details will be recorded. Full written informed consent will be obtained. Additional blood samples for safety will be collected at 1, 6, 24 and 72 hours (or hospital discharge) post-PCI/angiography. Blood samples for high-sensitive cardiac troponin T (upon arrival and 24 hours post PCI/angiography) and NT-ProBNP (24 hours post PCI/angiography) will be assessed by central laboratory. Follow up phone contacts will occur at 30 days to report AEs, bleeding events, and injection site reactions, and 12-months to record mortality, and hospitalizations for heart failure or atrial fibrillation, and [in the event of stroke], 90 days (±2 weeks) to record the stroke disability.

Angiography/PCI data and ECGs will be evaluated at independent Core Laboratories. An independent, blinded Clinical Events Committee will provide central adjudication of all clinical endpoint events. A DSMB will examine the safety data in an ongoing manner and to alert the Steering Committee in case of clinically concerning safety issues that should lead to consideration of altering the trial, and can recommend modification of the study protocol based on pre-specified rules.

The duration of participation for each subject will be 12 months (± 1 month), including enrollment, study drug administration, hospitalization, and phone contact follow-up at 30 days (+ 7 days) and 12 months (± 1 month).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2499 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single Subcutaneous Injection of Zalunfiban in Subjects With ST-elevation Myocardial Infarction in the Pre-hospital Setting
Actual Study Start Date : April 24, 2021
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: zalunfiban Dose 1 (0.110 mg/kg)
Subjects will receive a single subcutaneous injection containing zalunfiban Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
Drug: zalunfiban
zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
Other Name: RUC-4

Experimental: zalunfiban Dose 2 (0.130 mg/kg)
Subjects will receive a single subcutaneous injection containing zalunfiban Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
Drug: zalunfiban
zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
Other Name: RUC-4

Placebo Comparator: Placebo
Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival
Drug: Placebo
Single-use vials and syringes in randomization kits containing zalunfiban Dose 1 (0.110 mg/kg), zalunfiban Dose 2 (0.130 mg/kg), or placebo will be dispensed in the ambulance




Primary Outcome Measures :
  1. primary efficacy -clinical outcome [ Time Frame: at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo ]

    As assessed by a 7-point scale. The 7 outcomes, ranking from worst to best are:

    1. Death (all cause) at 30 days follow-up
    2. Stroke at 30 days follow-up
    3. Recurrent MI (type 1 to 4 MI) at 30 days follow-up
    4. Acute stent thrombosis at 24 hours post-PCI/angiography
    5. New onset heart failure or rehospitalization for heart failure at 30 days follow-up
    6. MI with hs-cTnT levels ≥10x ULN at 24 hours post-PCI/angiography
    7. None of the above

  2. primary safety- bleeding events [BARC criteria] [ Time Frame: after a single subcutaneous injection of zalunfiban versus placebo at 30 days post-PCI/angiography ]
    • To assess bleeding events (according to Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] severe or life threatening criterion for safety assessment and according to the Bleeding Academic Research Consortium [BARC] 3C and 5 criteria for information only)


Secondary Outcome Measures :
  1. secondary efficacy-restoration of the coronary artery blood flow [ Time Frame: before PCI (or coronary angiography if no PCI is performed) ]
    To assess restoration of the culprit coronary artery blood flow (corrected Thrombolysis in Myocardial Infarction [TIMI] Frame Count) before intended PCI (or post coronary angiography in case no PCI is performed) after a single subcutaneous injection of zalunfiban versus placebo

  2. efficacy-resolution of ST segment deviation [ Time Frame: 1 hour post-PCI/angiography ]
    To assess resolution of ST segment deviation post-PCI/angiography after a single subcutaneous injection of zalunfiban versus placebo

  3. Efficacy-composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist [ Time Frame: at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo ]
    To assess a composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist

  4. Efficacy-acute stent thrombosis [ Time Frame: up to 24 hours post-PCI ]
    To assess incidence of definite, probable or possible acute stent thrombosis after a single subcutaneous injection of zalunfiban versus placebo

  5. Safety throughout the study by AE reporting [ Time Frame: AEs up to 30 days follow-up; SAEs up to resolution/stabilization, the SAEs mortality, hospitalization for heart failure and atrial fibrillation up to 12-months follow-up ]
    Recording of AEs and SAEs fibrillation up to 12-months follow-up

  6. Safety-platelet count [ Time Frame: before PCI/angiography, at the end of the PCI/angiography, 6 and 24 hours post-PCI/angiography and at hospital discharge/72-hours post-PCI/angiography (whichever occurs first) ]
    To assess platelet count after a single subcutaneous injection of zalunfiban versus placebo

  7. Safety-bleeding events (ISTH and TIMI) [ Time Frame: at 30 days follow-up ]
    To assess bleeding events (according to International Society on Thrombosis and Haemostasis [ISTH] Major and TIMI Major for information only) after a single subcutaneous injection of zalunfiban versus placebo

  8. Safety-bleeding events (GUSTO mild and moderate, BARC type 2, 3 and 5, ISTH minor and/or major and TIMI minor and major) [ Time Frame: 30 days follow-up ]
    To assess incidence of bleeding events according to GUSTO mild and moderate criteria, BARC type 2, 3 and 5 criteria, ISTH minor and or major bleeding, TIMI minor and major criteria

  9. Safety-injection site reactions [ Time Frame: baseline, 1-hour post-PCI/angiography, hospital discharge/72-hours post-PCI/angiography, and at 30 days follow-up ]
    To assess the injection site reactions of a single subcutaneous injection of zalunfiban versus placebo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males aged ≥18 years or post-menopausal or surgically sterile females ≥50 years or ≥55 years (for Czech Republic study sites only).
  2. Weight (by history) between 52 and 130 kg.
  3. Subjects with STEMI, presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in two adjacent ECG leads, in whom the total duration of symptoms is 4 hours maximum. If time of symptom onset is uncertain, the cardiologist may be contacted to confirm inclusion criteria.
  4. Exception from Informed Consent Requirements (EFIC) process, verbal witnessed/ short written informed consent, or written informed consent signed by subject or legally authorized representative/independent witness will be obtained in the acute phase by (para)medics, according to local applicable legal regulations. Subject is willing and able to give informed consent. Written informed consent will be obtained as soon as the subject's clinical condition allows it.

Exclusion Criteria:

  1. Cardio Pulmonary Resuscitation (CPR) for current Out of Hospital Cardiac Arrest (OHCA).
  2. Presenting with systolic blood pressure <90 mmHg (confirmed on repeat assessment) and heart rate >100 beats per minute (bpm).
  3. Current known active coronavirus disease 2019 (COVID-19) infection (criteria according to local guidelines).
  4. Currently treated with renal dialysis.
  5. Current treatment with oral anticoagulation (Vitamin K antagonists [VKA] or direct oral anticoagulants [DOACs]).
  6. Major surgery, or trauma or bleeding leading to hospitalization, within the past month.
  7. Known history of ischemic or hemorrhagic stroke.
  8. Known severe anemia (regular blood transfusion needed).
  9. Previously enrolled in this study.
  10. Participation in another clinical study with an investigational product or device within the past month.
  11. Life expectancy less than one year.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04825743


Contacts
Layout table for location contacts
Contact: Robert S Hillman, PhD 8587779750 rhillman@celecor.com

Locations
Layout table for location information
Czechia
St. Anne's University hospital Recruiting
Brno, Czechia
Principal Investigator: M Rezek, MD PhD         
University Hospital Brno Recruiting
Brno, Czechia
Principal Investigator: Prof. P. Kala, MD PhD         
Netherlands
Zuyderland MC Recruiting
Heerlen, Limberg, Netherlands
Principal Investigator: S Rasoul, MD         
Jeroen Bosch Ziekenhuis Recruiting
's-Hertogenbosch, Netherlands
Principal Investigator: J Polad, MD         
Rijnstate Arnhem Recruiting
Arnhem, Netherlands
Principal Investigator: R Pisters, MD         
Tergooi Blaricum Recruiting
Blaricum, Netherlands
Principal Investigator: E K Arkenbout, MD         
Amphia Ziekenhuis Recruiting
Breda, Netherlands
Principal Investigator: B.J.L. van den Branden, MD         
Medisch Spectrum Twente Recruiting
Enschede, Netherlands
Principal Investigator: K G Van Houwelingen, MD PhD         
Maastricht UMC Recruiting
Maastricht, Netherlands
Principal Investigator: J Vainer, MD         
St. Antonius Ziekenhuis Recruiting
Nieuwegein, Netherlands, 3435 CM
Principal Investigator: J. M. Ten Berg, MD PhD         
ETZ TweeSteden Recruiting
Tilburg, Netherlands
Principal Investigator: B Zwart, MD         
UMC Utrecht Recruiting
Utrecht, Netherlands
Principal Investigator: G L Vlachojannis, MD         
Viecuri Medisch Centrum Recruiting
Venlo, Netherlands
Principal Investigator: W S Remkes, MD         
Isala Recruiting
Zwolle, Netherlands
Principal Investigator: R S Hermanides, MD PhD         
Sponsors and Collaborators
CeleCor Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Prof. Arnoud WJ Van 't Hof, MD PhD Maastricht University Medical Center
Layout table for additonal information
Responsible Party: CeleCor Therapeutics
ClinicalTrials.gov Identifier: NCT04825743    
Other Study ID Numbers: CEL-03
First Posted: April 1, 2021    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
ST Elevation Myocardial Infarction
Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases